Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Treatment options for IBS are limited, and only a few drugs have secured FDA approval specifically for IBS-D. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), and two recently approved agents: an antibiotic (Salix Pharmaceuticals’ Xifaxan) and an opioid delta receptor antagonist (Allergan’s Viberzi).
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
- How have Xifaxan and Viberzi been integrated into the treatment algorithm?
- What proportion of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with IBS-D?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.